<DOC>
	<DOCNO>NCT01487915</DOCNO>
	<brief_summary>Cisplatin-based chemotherapy standard regimen advance urothelial carcinoma . But cisplatin-unfit patient account 30-40 % patient clinical practice . Recently report phase II/III trial EORTC 30986 compare gemcitabine/carboplatin ( GCb ) MCAVI ( Methotrexate , Carboplatin , Vinblastine ) suggest GCb prefer regimen MCAVI base response rate , adverse event , severe acute toxicity . But grade 3 bad toxicity associate GCb infrequent need effective tolerable regimen . GemOx report effective favorable toxicity profile .</brief_summary>
	<brief_title>Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin Cisplatin-unfit Urothelial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Cytologically histologically confirm urothelial carcinoma Locally advance metastatic disease Measurable disease accord RECIST v.1.1 ECOG PS 02 Cisplatinunfit condition ( following : NYHA functional class 3 , creatinine clearance 3060 ml/min , ECOG PS=2 ) Adequate organ function Chemotherapynaive Histology urothelial carcinoma , squamous cell carcinoma adenocarcinoma mixed urothelial carcinoma allow CNS metastasis Peripheral neuropathy grade 2 worse Serious medical surgical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Cisplatin-unfit condition</keyword>
</DOC>